<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Palisaded neutrophilic and granulomatous dermatitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Palisaded neutrophilic and granulomatous dermatitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Palisaded neutrophilic and granulomatous dermatitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adela Rambi G Cardones, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H626103559"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Palisaded neutrophilic and granulomatous dermatitis (PNGD) is an inflammatory cutaneous disorder of unknown etiology that usually manifests as skin-colored to erythematous papules or plaques on the extremities (<a class="graphic graphic_picture graphicRef105736 graphicRef105738" href="/z/d/graphic/105736.html" rel="external">picture 1A-B</a>). PNGD typically occurs in association with systemic disease. Rheumatoid arthritis and systemic lupus erythematosus are the most common associated diseases.</p><p>The clinical features, diagnosis, and management of PNGD will be reviewed here. Other neutrophilic dermatoses are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5571.html" rel="external">"Neutrophilic dermatoses"</a>.)</p><p class="headingAnchor" id="H1262185"><span class="h1">HISTORY</span><span class="headingEndMark"> — </span>The term PNGD was first proposed in 1994 in a report describing a papular eruption on the extremities in several patients with systemic lupus erythematosus, rheumatoid arthritis, or uncharacterized collagen vascular disease [<a href="#rid1">1</a>]. Biopsies of involved skin revealed histopathologic findings consistent with an evolving immune complex disorder (see <a class="local">'Histopathology'</a> below). Prior cases of PNGD were classified under other names, including Churg-Strauss granuloma [<a href="#rid2">2</a>], linear subcutaneous bands [<a href="#rid3">3</a>], rheumatoid papules [<a href="#rid4">4</a>], superficial ulcerating rheumatoid necrobiosis [<a href="#rid5">5</a>], and cutaneous extravascular necrotizing granuloma of Winkelmann or Winkelmann granuloma [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H626103565"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>PNGD is rare. A 2008 literature review identified only 97 reported cases [<a href="#rid7">7</a>]. PNGD usually develops in adults; rarely, children are affected [<a href="#rid7">7,8</a>]. Women are affected more frequently than men, an observation that may be related to the association of PNGD with autoimmune diseases [<a href="#rid7">7</a>]. (See <a class="local">'Associated disorders'</a> below.)</p><p class="headingAnchor" id="H626103571"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of PNGD is unknown. Proposed theories for etiopathogenesis include abnormal neutrophil activation, circulating immune complex deposition, a delayed-hypersensitivity-type reaction, and a low-grade, small-vessel vasculitis [<a href="#rid8">8</a>]. Some authors have proposed that the clinical and histologic features of PNGD are manifestations of an evolving immune complex-mediated process [<a href="#rid1">1</a>]. In accordance with this theory, PNGD may represent an underlying leukocytoclastic vasculitis that acquires granulomatous features as the condition progresses [<a href="#rid1">1,7</a>]. </p><p class="headingAnchor" id="H626103577"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>PNGD is typically characterized by skin-colored to erythematous, smooth, papules and plaques on the elbows and extremities (<a class="graphic graphic_picture graphicRef105736 graphicRef105738" href="/z/d/graphic/105736.html" rel="external">picture 1A-B</a>) [<a href="#rid1">1,8</a>]. The papules and plaques are sometimes ulcerated or umbilicated. Other clinical manifestations include nodules, linear cords, urticarial or edematous plaques, erythematous or violaceous patches, and annular or gyrate papules and plaques. Associated scale is an infrequent finding.</p><p>Approximately one-half of patients with PNGD have involvement of the upper extremities [<a href="#rid7">7</a>]. Other potential sites of involvement, in order of decreasing frequency, are the lower extremities, trunk, and the head and neck [<a href="#rid7">7</a>].</p><p>PNGD is usually asymptomatic. However, pruritus or mild tenderness may occur [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H366658696"><span class="h1">ASSOCIATED DISORDERS</span><span class="headingEndMark"> — </span>PNGD usually develops in association with an underlying systemic inflammatory disorder [<a href="#rid10">10</a>]; rarely, PNGD occurs in the absence of systemic disease [<a href="#rid11">11</a>]. The onset of the associated systemic disease usually predates the diagnosis of PNGD [<a href="#rid12">12</a>].</p><p>The most common associated conditions are connective tissue disorders and arthritides, particularly systemic lupus erythematosus and rheumatoid arthritis [<a href="#rid1">1,7,8,12</a>]. The association among lupus patients is more pronounced among those who have lupus nephritis [<a href="#rid13">13</a>]. Other connective tissue disorders that have been present in patients with PNGD include limited systemic sclerosis [<a href="#rid7">7</a>], undifferentiated connective tissue disease, and vasculitides or vasculopathies, such as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, erythema elevatum diutinum, Takayasu arteritis, and mixed cryoglobulinemia [<a href="#rid8">8</a>]. PNGD has also been reported in association with ankylosing spondylitis [<a href="#rid14">14</a>] and adult-onset Still's disease [<a href="#rid15">15</a>].</p><p>There are occasional reports of PNGD in patients with hematologic disorders, including acute myelogenous leukemia, chronic myelomonocytic leukemia (CMML), multiple myeloma, and lymphoma [<a href="#rid6">6,16,17</a>]. At least four patients with CMML-associated PNGD have been found to have an <em>SRSF2</em> mutation [<a href="#rid18">18</a>]. </p><p>Other infrequently associated conditions include sarcoidosis [<a href="#rid19">19-21</a>], ulcerative colitis [<a href="#rid22">22</a>], celiac disease, type 1 diabetes [<a href="#rid23">23</a>], Behçet syndrome [<a href="#rid15">15</a>], multiple sclerosis, cellulitis [<a href="#rid24">24</a>], subacute bacterial endocarditis, hepatitis, streptococcal infections, and acquired immune deficiency syndrome (AIDS) [<a href="#rid7">7,8</a>]. There is one report of a patient with PNGD who presented with hypercalcemia in the absence of any identifiable underlying disease [<a href="#rid25">25</a>].</p><p>The possibility of drug-induced PNGD has been proposed based upon occurrences of PNGD after the initiation of tumor necrosis factor (TNF) inhibitor [<a href="#rid26">26,27</a>] or <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> therapy [<a href="#rid28">28</a>]. However, the patients received these drugs for rheumatoid arthritis or acute myelogenous leukemia, disorders that have been associated with PNGD.</p><p class="headingAnchor" id="H1262442"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>The histologic findings of PNGD are consistent with the evolution of an immune complex-mediated disorder [<a href="#rid1">1</a>]. Diffuse, pan-dermal infiltrates composed of neutrophils, nuclear debris, strands of amorphous deeply basophilic material with leukocytoclastic vasculitis, and palisaded granulomas are seen (<a class="graphic graphic_picture graphicRef105737" href="/z/d/graphic/105737.html" rel="external">picture 2</a>) [<a href="#rid1">1</a>]. The prominence of each of these findings may vary based upon the stage of disease. Palisaded granulomas may be most prevalent in mature lesions of PNGD [<a href="#rid1">1</a>]. Dermal mucin can be minimally increased, especially among those with an associated connective tissue disease, and fibrosis is not a prominent feature.</p><p>Some authors have described histopathologic features unique to patients with chronic myelomonocytic leukemia (CMML)-associated PNGD: a dense, wedge-shaped, dermal infiltrate with foamy and multinucleated histiocytes and focal areas of necrobiotic collagen [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H626103583"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of PNGD is made based upon correlation of the clinical and histologic findings. A skin biopsy should be performed in all patients. A 4 mm punch biopsy taken from a site of skin involvement is usually sufficient.</p><p>The diagnosis is most easily made in patients with all of the following features:</p><p class="bulletIndent1"><span class="glyph">●</span>A skin-colored or erythematous papular eruption on the extremities</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histologic findings of a neutrophilic infiltrate with leukocytoclastic vasculitis, palisaded granulomas, and collagen degeneration</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A known diagnosis of a systemic inflammatory disease associated with PNGD (eg, systemic lupus erythematosus or rheumatoid arthritis)</p><p></p><p>Patients [<a href="#rid1">1</a>] with cutaneous and histologic features of PNGD who lack a diagnosis of an associated systemic disease should be evaluated for systemic disease (see <a class="local">'Associated disorders'</a> above). In addition to a review of systems and physical examination with particular attention to signs and symptoms of systemic lupus erythematosus or rheumatoid arthritis, a reasonable initial work-up includes a chest radiograph and the following serologic studies [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Antinuclear antibodies</p><p class="bulletIndent1"><span class="glyph">●</span>Antineutrophil cytoplasmic antibody</p><p class="bulletIndent1"><span class="glyph">●</span>Rheumatoid factor</p><p class="bulletIndent1"><span class="glyph">●</span>Cyclic citrullinated peptide antibodies</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential</p><p></p><p>Rarely, PNGD has occurred in the absence of detectable systemic disease [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H626103589"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>PNGD should be distinguished from other cutaneous granulomatous disorders that may exhibit overlapping clinical features. Examples include granuloma annulare, interstitial granulomatous dermatitis, and interstitial granulomatous drug reaction. A skin biopsy is useful for distinguishing PNGD from these diseases:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Granuloma annulare </strong>–<strong> </strong>Granuloma annulare is a cutaneous disorder characterized by localized or generalized nonscaly erythematous papules or plaques on the trunk or extremities (<a class="graphic graphic_picture graphicRef71308" href="/z/d/graphic/71308.html" rel="external">picture 3</a>). Biopsies of granuloma annulare usually demonstrate a lymphocytic infiltrate, collagen degeneration, and mucin deposition in an interstitial or palisaded pattern (<a class="graphic graphic_picture graphicRef67442 graphicRef74645" href="/z/d/graphic/67442.html" rel="external">picture 4A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/13705.html" rel="external">"Granuloma annulare: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interstitial granulomatous drug reaction </strong>– Interstitial granulomatous drug reaction (IGDR) typically manifests as erythematous to violaceous annular or nonannular plaques with predilection for the inner upper arms, proximal inner thighs, trunk, and intertriginous skin. Histologic findings include an interstitial lymphohistiocytic infiltrate, fragmentation of collagen, interface dermatitis, tissue eosinophils, and atypical lymphocytes [<a href="#rid29">29</a>]. Vasculitis is typically absent. Multiple drugs have been implicated. Examples include calcium channel blockers, beta-blockers, lipid-lowering agents, angiotensin converting enzyme inhibitors, diuretics, and nonsteroidal antiinflammatory agents [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interstitial granulomatous dermatitis </strong>– Interstitial granulomatous dermatitis may present as skin-colored or erythematous rope-like linear cords, patches, plaques, or papules (<a class="graphic graphic_picture graphicRef52974" href="/z/d/graphic/52974.html" rel="external">picture 5</a>). Histopathologic examination typically reveals a histiocytic infiltrate in the dermis, foci of degenerated collagen, and granulomas [<a href="#rid8">8</a>]. Vasculitis is usually absent.</p><p></p><p>Some authors have proposed that PNGD and interstitial granulomatous dermatitis are part of the same clinicopathologic spectrum based upon overlap in clinical features, a shared association with systemic disease, and overlap in the histologic findings [<a href="#rid30">30</a>]. Others have proposed a new unifying term (reactive granulomatous dermatitis) to encompass PNGD, interstitial granulomatous dermatitis, and interstitial granulomatous drug reaction [<a href="#rid8">8,12,31,32</a>].</p><p class="headingAnchor" id="H626103595"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>PNGD is a non-life-threatening cutaneous disorder that often resolves spontaneously or with treatment of the underlying associated disease. Therefore, treatment specifically for PNGD often is not necessary. (See <a class="local">'Prognosis'</a> below.)</p><p>Because of the rarity of PNGD, there are no prospective therapeutic clinical trials evaluating the efficacy of interventions for persistent PNGD. Clinical experience suggests that PNGD may improve with oral <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> [<a href="#rid33">33,34</a>], oral <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> [<a href="#rid8">8</a>], or systemic glucocorticoid therapy [<a href="#rid7">7,35</a>]. Local therapies that may result in improvement include topical corticosteroid and intralesional corticosteroid therapy [<a href="#rid34">34,36,37</a>].</p><p>Other therapies have been proposed. A patient with rheumatoid arthritis who developed tocilizumab-associated PNGD improved during treatment with <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a> [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H626103601"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Prognostic data on PNGD are limited. Spontaneous resolution of PNGD can occur within a period as short as a few weeks or after longer periods of time [<a href="#rid7">7</a>]. In a review of 92 reported cases of PNGD, 20 percent of the 25 patients with available clinical response data had evidence of spontaneous resolution. Treatment responses were favorable among the remaining 20 patients; 80 percent responded to systemic treatment, which in most cases was directed at the underlying disease [<a href="#rid7">7</a>]. Recurrence after resolution is possible [<a href="#rid7">7,9</a>].</p><p class="headingAnchor" id="H626103613"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Palisaded neutrophilic and granulomatous dermatitis (PNGD) is a rare cutaneous disorder that usually occurs in association with systemic disease. It is postulated that the pathogenesis of PNGD involves an immune-complex mediated leukocytoclastic vasculitis that progresses to develop granulomatous features. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The most common clinical manifestations of PNGD are skin-colored to erythematous smooth papules or plaques (<a class="graphic graphic_picture graphicRef105736 graphicRef105738" href="/z/d/graphic/105736.html" rel="external">picture 1A-B</a>). The upper extremities are the most frequent site of involvement. PNGD is usually asymptomatic, but may be associated with pruritus or tenderness of involved skin. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated disorders</strong> – Rheumatoid arthritis and systemic lupus erythematosus are the most common underlying diseases in patients with PNGD. PNGD may also occur in association with other connective tissue disorders, hematologic disorders, and other diseases. (See <a class="local">'Associated disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of PNGD is made based upon the detection of consistent clinical and histologic findings. Therefore, a skin biopsy is required for diagnosis. The characteristic histologic features are an intense neutrophilic dermal infiltrate, leukocytoclastic vasculitis, palisaded granulomas, and collagen degeneration (<a class="graphic graphic_picture graphicRef105737" href="/z/d/graphic/105737.html" rel="external">picture 2</a>). (See <a class="local">'Histopathology'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – PNGD usually resolves spontaneously or during treatment of the underlying disease. The best approach to persistent PNGD is unclear. Clinical experience suggests oral <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, systemic glucocorticoids, and topical or intralesional corticosteroids may be beneficial treatments. (See <a class="local">'Management'</a> above and <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chu P, Connolly MK, LeBoit PE. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol 1994; 130:1278.</a></li><li><a class="nounderline abstract_t">Dicken CH, Winkelmann RK. The Churg-Strauss granuloma: cutaneous, necrotizing, palisading granuloma in vasculitis syndromes. Arch Pathol Lab Med 1978; 102:576.</a></li><li><a class="nounderline abstract_t">DYKMAN CJ, GALENS GJ, GOOD AE. LINEAR SUBCUTANEOUS BANDS IN RHEUMATOID ARTHRITIS. AN UNUSUAL FORM OF RHEUMATOID GRANULOMA. Ann Intern Med 1965; 63:134.</a></li><li><a class="nounderline abstract_t">Smith ML, Jorizzo JL, Semble E, et al. Rheumatoid papules: lesions showing features of vasculitis and palisading granuloma. J Am Acad Dermatol 1989; 20:348.</a></li><li><a class="nounderline abstract_t">Jorizzo JL, Olansky AJ, Stanley RJ. Superficial ulcerating necrobiosis in rheumatoid arthritis. A variant of the necrobiosis lipoidica-rheumatoid nodule spectrum? Arch Dermatol 1982; 118:255.</a></li><li><a class="nounderline abstract_t">Finan MC, Winkelmann RK. The cutaneous extravascular necrotizing granuloma (Churg-Strauss granuloma) and systemic disease: a review of 27 cases. Medicine (Baltimore) 1983; 62:142.</a></li><li><a class="nounderline abstract_t">Hantash BM, Chiang D, Kohler S, Fiorentino D. Palisaded neutrophilic and granulomatous dermatitis associated with limited systemic sclerosis. J Am Acad Dermatol 2008; 58:661.</a></li><li><a class="nounderline abstract_t">Rosenbach M, English JC 3rd. Reactive Granulomatous Dermatitis: A Review of Palisaded Neutrophilic and Granulomatous Dermatitis, Interstitial Granulomatous Dermatitis, Interstitial Granulomatous Drug Reaction, and a Proposed Reclassification. Dermatol Clin 2015; 33:373.</a></li><li><a class="nounderline abstract_t">Bremner R, Simpson E, White CR, et al. Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders. Semin Arthritis Rheum 2004; 34:610.</a></li><li><a class="nounderline abstract_t">Wilmoth GJ, Perniciaro C. Cutaneous extravascular necrotizing granuloma (Winkelmann granuloma): confirmation of the association with systemic disease. J Am Acad Dermatol 1996; 34:753.</a></li><li><a class="nounderline abstract_t">Misago N, Shinoda Y, Tago M, Narisawa Y. Palisaded neutrophilic granulomatous dermatitis with leukocytoclastic vasculitis in a patient without any underlying systemic disease detected to date. J Cutan Pathol 2010; 37:1092.</a></li><li><a class="nounderline abstract_t">Bangalore Kumar A, Lehman JS, Johnson EF, et al. Reactive granulomatous dermatitis as a clinically relevant and unifying term: a retrospective review of clinical features, associated systemic diseases, histopathology and treatment for a series of 65 patients at Mayo Clinic. J Eur Acad Dermatol Venereol 2022; 36:2443.</a></li><li><a class="nounderline abstract_t">Terai S, Ueda-Hayakawa I, Nguyen CTH, et al. Palisaded neutrophilic and granulomatous dermatitis associated with systemic lupus erythematosus: possible involvement of CD163+ M2 macrophages in two cases, and a review of published works. Lupus 2018; 27:2220.</a></li><li><a class="nounderline abstract_t">de Unamuno Bustos B, Rabasco AG, Sánchez RB, de Miquel VA. Palisaded neutrophilic and granulomatous dermatitis associated with ankylosing spondylitis. Am J Dermatopathol 2013; 35:847.</a></li><li><a class="nounderline abstract_t">Kim SK, Park CK, Park YW, et al. Palisaded neutrophilic granulomatous dermatitis presenting as an unusual skin manifestation in a patient with Behçet's disease. Scand J Rheumatol 2005; 34:324.</a></li><li><a class="nounderline abstract_t">Calonje JE, Greaves MW. Cutaneous extravascular necrotizing granuloma (Churg-Strauss) as a paraneoplastic manifestation of non-Hodgkin's B-cell lymphoma. J R Soc Med 1993; 86:549.</a></li><li><a class="nounderline abstract_t">Federmann B, Bonzheim I, Yazdi AS, et al. Generalized palisaded neutrophilic and granulomatous dermatitis-a cutaneous manifestation of chronic myelomonocytic leukemia? A clinical, histopathological, and molecular study of 3 cases. Hum Pathol 2017; 64:198.</a></li><li><a class="nounderline abstract_t">Enescu CD, Patel A, Friedman BJ. Unique Recognizable Histopathologic Variant of Palisaded Neutrophilic and Granulomatous Dermatitis that Is Associated With SRSF2-Mutated Chronic Myelomonocytic Leukemia: Case Report and Review of the Literature. Am J Dermatopathol 2022; 44:e33.</a></li><li><a class="nounderline abstract_t">Mahmoodi M, Ahmad A, Bansal C, Cusack CA. Palisaded neutrophilic and granulomatous dermatitis in association with sarcoidosis. J Cutan Pathol 2011; 38:365.</a></li><li><a class="nounderline abstract_t">Gordon EA, Schmidt AN, Boyd AS. Palisaded neutrophilic and granulomatous dermatitis: a presenting sign of sarcoidosis? J Am Acad Dermatol 2011; 65:664.</a></li><li><a class="nounderline abstract_t">Paštar Z, Radoš J, Pavić I, et al. Palisaded neutrophilic and granulomatous dermatitis in association with subcutaneous nodular and systemic sarcoidosis. Acta Dermatovenerol Croat 2013; 21:245.</a></li><li><a class="nounderline abstract_t">Asahina A, Fujita H, Fukunaga Y, et al. Early lesion of palisaded neutrophilic granulomatous dermatitis in ulcerative colitis. Eur J Dermatol 2007; 17:234.</a></li><li><a class="nounderline abstract_t">Biswas A, Chittari K, Gey van Pittius D, et al. Palisaded neutrophilic and granulomatous dermatitis in a child with type I diabetes mellitus and coeliac disease. Br J Dermatol 2008; 159:488.</a></li><li><a class="nounderline abstract_t">Misago N, Narisawa Y, Tada Y, Nagasawa K. Palisaded neutrophilic granulomatous dermatitis caused by cellulitis in a patient with systemic lupus erythematosus. Int J Dermatol 2011; 50:1583.</a></li><li><a class="nounderline abstract_t">Kono M, Hasegawa T, Nagai S, et al. Palisaded neutrophilic and granulomatous dermatitis as a novel cause of hypercalcemia: A case report. Medicine (Baltimore) 2017; 96:e6968.</a></li><li><a class="nounderline abstract_t">Umezawa Y, Ito K, Nakagawa H. Palisaded neutrophilic and granulomatous dermatitis in a rheumatoid arthritis patient after treatment with adalimumab. Eur J Dermatol 2013; 23:910.</a></li><li><a class="nounderline abstract_t">Stephenson SR, Campbell SM, Drew GS, Magro CM. Palisaded neutrophilic and granulomatous dermatitis presenting in a patient with rheumatoid arthritis on adalimumab. J Cutan Pathol 2011; 38:644.</a></li><li><a class="nounderline abstract_t">Gordon K, Miteva M, Torchia D, Romanelli P. Allopurinol-induced palisaded neutrophilic and granulomatous dermatitis. Cutan Ocul Toxicol 2012; 31:338.</a></li><li><a class="nounderline abstract_t">Magro CM, Crowson AN, Schapiro BL. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol 1998; 25:72.</a></li><li><a class="nounderline abstract_t">Coutinho I, Pereira N, Gouveia M, et al. Interstitial Granulomatous Dermatitis: A Clinicopathological Study. Am J Dermatopathol 2015; 37:614.</a></li><li><a class="nounderline abstract_t">Wanat KA, Caplan A, Messenger E, et al. Reactive granulomatous dermatitis: A useful and encompassing term. JAAD Int 2022; 7:126.</a></li><li><a class="nounderline abstract_t">Rodríguez-Garijo N, Bielsa I, Mascaró JM Jr, et al. Reactive granulomatous dermatitis as a histological pattern including manifestations of interstitial granulomatous dermatitis and palisaded neutrophilic and granulomatous dermatitis: a study of 52 patients. J Eur Acad Dermatol Venereol 2021; 35:988.</a></li><li><a class="nounderline abstract_t">Fett N, Kovarik C, Bennett D. Palisaded neutrophilic granulomatous dermatitis without a definable underlying disorder treated with dapsone. J Am Acad Dermatol 2011; 65:e92.</a></li><li><a class="nounderline abstract_t">He Y, Maverakis E, Ramirez-Maverakis D, Fitzmaurice S. Combination therapy with intralesional triamcinolone and oral dapsone for management of palisaded neutrophilic and granulomatous dermatitis. Dermatol Online J 2013; 19:17.</a></li><li><a class="nounderline abstract_t">Al-Daraji WI, Coulson IH, Howat AJ. Palisaded neutrophilic and granulomatous dermatitis. Clin Exp Dermatol 2005; 30:578.</a></li><li><a class="nounderline abstract_t">Collaris EJ, van Marion AM, Frank J, Poblete-Gutiérrez P. Cutaneous granulomas in rheumatoid arthritis. Int J Dermatol 2007; 46 Suppl 3:33.</a></li><li><a class="nounderline abstract_t">Brecher A. Palisaded neutrophilic and granulomatous dermatitis. Dermatol Online J 2003; 9:1.</a></li><li><a class="nounderline abstract_t">Chung WH, Chen CB, Chan TM. Baricitinib Treatment for Palisaded Neutrophilic Granulomatous Dermatitis: A New Paradoxical Reaction to Tocilizumab. Dermatitis 2023; 34:466.</a></li></ol></div><div id="topicVersionRevision">Topic 100660 Version 5.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7944509" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/581451" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Churg-Strauss granuloma: cutaneous, necrotizing, palisading granuloma in vasculitis syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14305961" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : LINEAR SUBCUTANEOUS BANDS IN RHEUMATOID ARTHRITIS. AN UNUSUAL FORM OF RHEUMATOID GRANULOMA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2644322" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rheumatoid papules: lesions showing features of vasculitis and palisading granuloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7065682" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Superficial ulcerating necrobiosis in rheumatoid arthritis. A variant of the necrobiosis lipoidica-rheumatoid nodule spectrum?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6843354" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The cutaneous extravascular necrotizing granuloma (Churg-Strauss granuloma) and systemic disease: a review of 27 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17945384" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Palisaded neutrophilic and granulomatous dermatitis associated with limited systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26143420" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reactive Granulomatous Dermatitis: A Review of Palisaded Neutrophilic and Granulomatous Dermatitis, Interstitial Granulomatous Dermatitis, Interstitial Granulomatous Drug Reaction, and a Proposed Reclassification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15609265" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8632069" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cutaneous extravascular necrotizing granuloma (Winkelmann granuloma): confirmation of the association with systemic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903215" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Palisaded neutrophilic granulomatous dermatitis with leukocytoclastic vasculitis in a patient without any underlying systemic disease detected to date.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35535506" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Reactive granulomatous dermatitis as a clinically relevant and unifying term: a retrospective review of clinical features, associated systemic diseases, histopathology and treatment for a series of 65 patients at Mayo Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30376790" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Palisaded neutrophilic and granulomatous dermatitis associated with systemic lupus erythematosus: possible involvement of CD163+ M2 macrophages in two cases, and a review of published works.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23974221" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Palisaded neutrophilic and granulomatous dermatitis associated with ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16195168" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Palisaded neutrophilic granulomatous dermatitis presenting as an unusual skin manifestation in a patient with Behçet's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8410900" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cutaneous extravascular necrotizing granuloma (Churg-Strauss) as a paraneoplastic manifestation of non-Hodgkin's B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28442268" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Generalized palisaded neutrophilic and granulomatous dermatitis-a cutaneous manifestation of chronic myelomonocytic leukemia? A clinical, histopathological, and molecular study of 3 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34783709" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Unique Recognizable Histopathologic Variant of Palisaded Neutrophilic and Granulomatous Dermatitis that Is Associated With SRSF2-Mutated Chronic Myelomonocytic Leukemia: Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20528967" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Palisaded neutrophilic and granulomatous dermatitis in association with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21839329" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Palisaded neutrophilic and granulomatous dermatitis: a presenting sign of sarcoidosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24476612" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Palisaded neutrophilic and granulomatous dermatitis in association with subcutaneous nodular and systemic sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17483043" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Early lesion of palisaded neutrophilic granulomatous dermatitis in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18503597" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Palisaded neutrophilic and granulomatous dermatitis in a child with type I diabetes mellitus and coeliac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22098012" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Palisaded neutrophilic granulomatous dermatitis caused by cellulitis in a patient with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28538395" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Palisaded neutrophilic and granulomatous dermatitis as a novel cause of hypercalcemia: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24201093" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Palisaded neutrophilic and granulomatous dermatitis in a rheumatoid arthritis patient after treatment with adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21592182" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Palisaded neutrophilic and granulomatous dermatitis presenting in a patient with rheumatoid arthritis on adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22250812" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Allopurinol-induced palisaded neutrophilic and granulomatous dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521495" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25830722" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Interstitial Granulomatous Dermatitis: A Clinicopathological Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35434665" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reactive granulomatous dermatitis: A useful and encompassing term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33098595" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Reactive granulomatous dermatitis as a histological pattern including manifestations of interstitial granulomatous dermatitis and palisaded neutrophilic and granulomatous dermatitis: a study of 52 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21839310" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Palisaded neutrophilic granulomatous dermatitis without a definable underlying disorder treated with dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23473287" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Combination therapy with intralesional triamcinolone and oral dapsone for management of palisaded neutrophilic and granulomatous dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16045697" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Palisaded neutrophilic and granulomatous dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17973887" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cutaneous granulomas in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14594574" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Palisaded neutrophilic and granulomatous dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35482285" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Baricitinib Treatment for Palisaded Neutrophilic Granulomatous Dermatitis: A New Paradoxical Reaction to Tocilizumab.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
